Sector
PharmaceuticalsOpen
₹1,772Prev. Close
₹1,777.25Turnover(Lac.)
₹35,855.07Day's High
₹1,791.45Day's Low
₹1,758.0552 Week's High
₹1,960.3552 Week's Low
₹1,184.5Book Value
₹103.34Face Value
₹1Mkt Cap (₹ Cr.)
4,27,081.62P/E
154.5EPS
11.49Divi. Yield
0.76Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.
The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.
IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.
The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 239.93 | 239.93 | 239.93 | 239.93 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 23,454.47 | 23,508.43 | 24,348.02 | 26,698.54 |
Net Worth | 23,694.4 | 23,748.36 | 24,587.95 | 26,938.47 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 15,585.98 | 14,116.05 | 12,531.93 | 7,923.84 |
yoy growth (%) | 10.41 | 12.64 | 58.15 | 3.12 |
Raw materials | -5,650.39 | -5,107.48 | -4,567.72 | -3,492.77 |
As % of sales | 36.25 | 36.18 | 36.44 | 44.07 |
Employee costs | -2,000.78 | -1,805.98 | -1,702.77 | -1,617.69 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 2,127.39 | 945.13 | 3,253 | 430.52 |
Depreciation | -1,349.95 | -1,236.43 | -561.56 | -432.23 |
Tax paid | -406.85 | -13.17 | -41.86 | 25.39 |
Working capital | -5,179.41 | -888.49 | 3,200.15 | 1,619.85 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 10.41 | 12.64 | 58.15 | 3.12 |
Op profit growth | 28.82 | -16.76 | 2,104.23 | 7.94 |
EBIT growth | 107.43 | -66.87 | 347.1 | 296.01 |
Net profit growth | -111.86 | -73.76 | -749.25 | 2,065.45 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 47,758.45 | 43,278.87 | 38,426.42 | 33,233.08 | 32,325.17 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 47,758.45 | 43,278.87 | 38,426.42 | 33,233.08 | 32,325.17 |
Other Operating Income | 738.4 | 606.81 | 228.07 | 265.06 | 512.33 |
Other Income | 1,354.19 | 634.52 | 921.51 | 835.52 | 635.98 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,780 | 154.5 | 4,25,929.94 | 863.29 | 0.76 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,977.1 | 85.2 | 1,56,524.26 | 518 | 0.51 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,465.5 | 28.06 | 1,18,825.56 | 1,178.16 | 0.88 | 3,969.86 | 360.74 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,101.95 | 64.02 | 1,04,737.39 | 460 | 0.9 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,558.65 | 51.33 | 1,02,885.42 | 634.43 | 0 | 2,529.74 | 269.24 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Dilip S Shanghvi
Non-Exec & Non-Independent Dir
Sudhir V Valia
Non-Exec. & Independent Dir.
Gautam Doshi
Lead Independent Director
Pawan Goenka
Independent Director
Rama Bijapurkar
Company Sec. & Compli. Officer
Anoop Deshpande
Independent Director
Sanjay K Asher
Independent Director
Rolf Hoffmann
Whole Time Director
Aalok Shanghvi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Sun Pharmaceuticals Industries Ltd
Summary
Sun Pharmaceutical Industries Limited including its subsidiaries and associates (Sun Pharma) is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.The company has global presence with 43 manufacturing facilities across the world. India and the US are two predominant markets, accounting for nearly 70% of the companys revenue. The company has a robust product pipeline and established presence in Europe and high-growth emerging markets like Russia, Romania, South Africa, Brazil a
Read More
The Sun Pharmaceuticals Industries Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1780 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharmaceuticals Industries Ltd is ₹427081.62 Cr. as of 21 Nov ‘24
The PE and PB ratios of Sun Pharmaceuticals Industries Ltd is 154.5 and 18.05 as of 21 Nov ‘24
The 52-week high/low is the highest and lowest price at which a Sun Pharmaceuticals Industries Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sun Pharmaceuticals Industries Ltd is ₹1184.5 and ₹1960.35 as of 21 Nov ‘24
Sun Pharmaceuticals Industries Ltd's CAGR for 5 Years at 33.07%, 3 Years at 32.11%, 1 Year at 49.60%, 6 Month at 15.33%, 3 Month at 1.68% and 1 Month at -6.31%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice